KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.

Daniela E Matei, Danielle M Enserro, Marcus E Randall, David Mutch, William Small, Paul A DiSilvestro, Nick M Spirtos, David M O'Malley, Guilherme H Cantuaria, David Michelin, Steven Waggoner, Mark Shahin, Saketh Guntupalli, Olivia Lara, Frederick R Ueland, David Warshal, Albert Bonebrake, Krishnansu S Tewari, Annie Tan, Matthew A Powell, Joan L Walker, Alessandro D Santin, Jong Hyeok Kim, David S Miller

J Clin Oncol 43(9) 1055-1060

PMID39700442
PMCIDPMC11908887
DOI10.1200/JCO.24.01121
发表日期2024-12-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and overall survival (OS) when compared with carboplatin and paclitaxel for six cycles (chemotherapy [CT]) in locally advanced endometrial cancer (UC). Previously reported results showed that C-RT did not improve RFS compared with CT. Here we report the final OS analysis. Patients with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage III-IVA UC or stage I/II serous or clear cell UC and positive cytology were enrolled. The primary objective was RFS. Secondary objectives were OS, toxicity, and quality of life. Cumulative probabilities of OS were estimated using the Kaplan-Meier method. Subgroup analyses of treatment effect for FIGO stage, age, race, gross residual disease, histology, lymph-vascular space invasion, and body mass index were performed. In total, 813 patients were randomly assigned (407 C-RT and 406 CT). The median follow-up was 112 months. Median OS was not achieved in either arm. The stratified hazard ratio for death comparing C-RT versus CT was 1.05 (95% CI, 0.82 to 1.34, log-rank two-sided P value = .72). None of the factors analyzed predicted OS benefit from C-RT. Although C-RT reduced the rate of local recurrence compared with CT, it did not increase OS or RFS in stage III/IVA UC.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1:

Kaplan Meyer estimates of overall survival for patients enrolled on C-RT and CT arms.

Overall_Survival

overall survival

Figure 1: · Panel Overall_Survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_Survival 是同一 Figure 1: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2:Forest plot indicates Overall Survival (OS) subgroup analysis according to the prognostic factors: age, race, BMI, histological subtype and grade, presence of LVSI, surgical stage, and gross residual disease. P-values presented are for testing the interaction between subgroup variable and treatment.
非 KM Figure